TAP Block for Postoperative Pain in Endometrial Cancer Surgery
Trial Summary
What is the purpose of this trial?
Modern postoperative pain management aims to optimizing pain relief while minimizing opiate usage. While opiates are effective for pain relief, they result in common adverse effects such as nausea, constipation, and urinary retention, and most importantly present a long-term risk of abuse and dependency. Commonly used approaches include non-opiate pain medications such as acetominophen and non-steroidal anti-inflammatory agents, as well as regional nerve blocks such as epidurals. The transversus abdominis plane (TAP) block is a fascial plane block performed by injecting local anesthetic into the plane superficial to the transversus abdominis muscle where the anterior rami of the spinal nerves course to provide sensory innervation to the abdominal wall. The injections are generally placed either subcostally or at the midaxillary line bilaterally. The TAP block has been shown to be effective in reducing pain scores and opiate usage in some randomized studies but not others in patients undergoing various abdominal surgeries. There is great variation in method of administration, sites injected, and local anesthetics used, which may in part account for the heterogeneity of trial results.
Research Team
Young B Kim, MD
Principal Investigator
Tufts Medical Center
Eligibility Criteria
This trial is for women aged 18-80 undergoing minimally invasive hysterectomy for endometrial cancer or pre-cancer, who can consent to the study. It excludes those with severe allergies to bupivacaine, high surgical risk (ASA IV/V), emergency surgery cases, pregnant or breastfeeding women, non-endometrial cancer surgeries, chronic opiate users, and those with serious liver or kidney issues.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Bupivacaine (Local Anesthetic)
- Liposomal Bupivacaine (Local Anesthetic)
- Transversus Abdominis Plane (TAP) Block (Local Anesthetic)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Tufts Medical Center
Lead Sponsor
Michael Dandorph
Tufts Medical Center
Chief Executive Officer since 2022
MBA
Helen Boucher
Tufts Medical Center
Chief Medical Officer since 2022
MD, FACP, FIDSA